WhatsApp used in research, but is this ethical?

By HEOR Staff Writer

March 15, 2023

Globally, WhatsApp Messenger has emerged as one of the world’s fastest-growing MIM applications. It has particularly high penetration rates in India, Indonesia, Malaysia, Brazil and South Africa.

The sub-Saharan African region is characterized by mixed migration flows and multiple health challenges, due to the inequalities experienced in access to healthcare disproportionately affect many groups including migrants and mobile populations. Given the existing structural factors impeding access to healthcare, coupled with high rates of mobile telephone use across the sub-Saharan African region; mobile phones are consistently recognized as having great potential for improving access to healthcare in this context.

WhatsApp was largely used in one of two ways for health research; to send hyperlinks to online surveys, or to deliver and evaluate, either an intervention designed for healthcare users or a communication programme for healthcare providers.

Challenges include efforts taken to ensure privacy, confidentiality and anonymity when using WhatsApp as a data collection tool; significant gender divide in access to mobile phones, with men being far more likely to have access to a device than women; features in WhatsApp that could potentially allow some encrypted messages to be read by unintended recipients, compounding the possible breaches of WhatsApp data.

Reference url

Recent Posts

Advancing Participatory Arts Health in Dutch Care Systems

By João L. Carapinha

March 30, 2026

Participatory arts health is gaining recognition as a valuable complement to traditional medical care, supporting both physical and psychosocial well-being for people living with chronic conditions and those at the end of life. In this article we explore how creative, participatory approaches ...
Advancing Tarlatamab for Small Cell Lung Cancer Treatment
New Treatment Option for Relapsed Extensive-Stage Small Cell Lung Cancer Tarlatamab small cell lung therapy has received a positive opinion from the European Medicines Agency (EMA) for marketing authorisation. The bispecific T-cell engager is recommended as monotherapy ...
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application Amid Regulatory Hurdles

By João L. Carapinha

March 26, 2026

Anavex Life Sciences has withdrawn its marketing authorization application for blarcamesine in early Alzheimer’s disease following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). EU Alzheimer Approval Challenges remain a significant hurdle for ...